Abstract
Moving to multigene testing for all women with breast cancer (BC) could identify many more mutation carriers who can benefit from precision prevention. However, the cost-effectiveness of this approach remains unaddressed. To estimate incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with BC compared with the current practice of genetic testing (BRCA) based on family history (FH) or clinical criteria. This cost-effectiveness microsimulation modeling study compared lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of all unselected patients with BC (strategy A) with BRCA1/BRCA2 testing based on FH or clinical criteria (strategy B) in United Kingdom (UK) and US populations. Data were obtained from 11 836 patients in population-based BC cohorts (regardless of FH) recruited to 4 large research studies. Data were collected and analyzed from January 1, 2018, through June 8, 2019. The time horizon is lifetime. Payer and societal perspectives are presented. Probabilistic and 1-way sensitivity analyses evaluate model uncertainty. In strategy A, all women with BC underwent BRCA1/BRCA2/PALB2 testing. In strategy B, only women with BC fulfilling FH or clinical criteria underwent BRCA testing. Affected BRCA/PALB2 carriers could undertake contralateral preventive mastectomy; BRCA carriers could choose risk-reducing salpingo-oophorectomy (RRSO). Relatives of mutation carriers underwent cascade testing. Unaffected relative carriers could undergo magnetic resonance imaging or mammography screening, chemoprevention, or risk-reducing mastectomy for BC risk and RRSO for ovarian cancer (OC) risk. Incremental cost-effectiveness ratio (ICER) was calculated as incremental cost per quality-adjusted life-year (QALY) gained and compared with standard £30 000/QALY and $100 000/QALY UK and US thresholds, respectively. Incidence of OC, BC, excess deaths due to heart disease, and the overall population effects were estimated. BRCA1/BRCA2/PALB2 multigene testing for all patients detected with BC annually would cost £10 464/QALY (payer perspective) or £7216/QALY (societal perspective) in the United Kingdom or $65 661/QALY (payer perspective) or $61 618/QALY (societal perspective) in the United States compared with current BRCA testing based on clinical criteria or FH. This is well below UK and US cost-effectiveness thresholds. In probabilistic sensitivity analysis, unselected multigene testing remained cost-effective for 98% to 99% of UK and 64% to 68% of US health system simulations. One year's unselected multigene testing could prevent 2101 cases of BC and OC and 633 deaths in the United Kingdom and 9733 cases of BC and OC and 2406 deaths in the United States. Correspondingly, 8 excess deaths due to heart disease occurred in the United Kingdom and 35 in the United States annually. This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.
Highlights
BRCA1/BRCA2/PALB2 multigene testing for all patients detected with breast cancer (BC) annually would cost £10 464/quality-adjusted life-year (QALY) or £7216/QALY in the United Kingdom or $65 661/QALY or $61 618/QALY in the United States compared with current BRCA testing based on clinical criteria or family history (FH)
This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for United Kingdom (UK) and US health systems
Being a BRCA carrier refers to carrying an inheritable genetic pathogenic variant that predisposes to development of BRCAassociated cancers
Summary
This analysis received full ethics approval from the Institute of Child Health/Great Ormond Street Hospital Research Ethics Committee as well as the London School of Hygiene and Tropical Medicine Ethics Committee, waiving informed consent for the use of anonymized data. We obtained data on FH by age from 11 836 women diagnosed with invasive BC, including (1) 1389 unselected patients with BC older than 45 years who were identified among 57 902 women in the Predicting Risk of Breast Cancer Screening study, a large-scale study within the Greater Manchester UK National Health Service Breast Screening Programme[20]; (2) 2885 patients with BC younger than 40 years from 127 UK hospitals in the Prospective Outcomes in Sporadic vs Hereditary Breast Cancer study[21]; (3) 5892 unselected patients with BC older than 40 years among 132 139 women enrolled in the Kaiser Permanente Washington Breast Cancer Surveillance Consortium registry who underwent mammography screening from 1996 to 201422; and (4) 1670 patients with BC younger and older than 40 years who were randomly selected from the unselected population–based BC cases jamaoncology.com (Reprinted) JAMA Oncology December 2019 Volume 5, Number 12 1719.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
